Rexon Laboratories Profile
Key Indicators
- Authorised Capital ₹ 3.50 Cr
as on 05-12-2024
- Paid Up Capital ₹ 1.41 Cr
as on 05-12-2024
- Company Age 29 Year, 5 Months
- Last Filing with ROC 31 Mar 2021
- Open Charges ₹ 40.45 Cr
as on 05-12-2024
- Revenue 11.86%
(FY 2020)
- Profit -9.43%
(FY 2020)
- Ebitda -2.82%
(FY 2020)
- Net Worth 5.36%
(FY 2020)
- Total Assets 4.38%
(FY 2020)
About Rexon Laboratories
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2021. It's a company limited by shares with an authorized capital of Rs 3.50 Cr and a paid-up capital of Rs 1.41 Cr.
The company currently has active open charges totaling ₹40.45 Cr.
Rakesh Sharma, Pankaj Sharma, Vijay Bharat, and One other member serve as directors at the Company.
- CIN/LLPIN
U51909PB1995PLC016718
- Company No.
016718
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
05 Jul 1995
- Date of AGM
30 Nov 2021
- Date of Balance Sheet
31 Mar 2021
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- LocationJalandhar, Punjab
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Rexon Laboratories?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rakesh Sharma  | Managing Director | 05-Jul-1995 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Karan Sharma | Director | 05-Jan-2019 | Current |
| Pankaj Sharma | Director | 06-Feb-2000 | Current |
| Vijay Bharat | Director | 29-Sep-2001 | Current |
Financial Performance of Rexon Laboratories.
Rexon Laboratories Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 11.86% increase. The company also saw a slight decrease in profitability, with a 9.43% decrease in profit. The company's net worth moved up by a moderate rise of 5.36%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rexon Laboratories?
In 2020, Rexon Laboratories had a promoter holding of 73.16% and a public holding of 26.84%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 30 Mar 2021 | ₹1.00 Cr | Open |
Others Creation Date: 15 Jul 2020 | ₹1.50 Cr | Open |
Others Creation Date: 02 Jul 2020 | ₹5.50 M | Open |
How Many Employees Work at Rexon Laboratories?
Unlock and access historical data on people associated with Rexon Laboratories, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rexon Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rexon Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
